Literature DB >> 9016396

Potential involvement of kallikrein hK2 in the hydrolysis of the human seminal vesicle proteins after ejaculation.

D Deperthes1, G Frenette, M Brillard-Bourdet, L Bourgeois, F Gauthier, R R Tremblay, J Y Dubé.   

Abstract

We have recently demonstrated in liquefied human seminal plasma the presence of the novel kallikrein hK2 in association with protein C inhibitor (PCI) as a 75-kDa complex. In the present study, we showed that hK2, immediately after ejaculation, was recovered only in its free form but complex formation with PCI occurred rapidly thereafter and was completed within 10 minutes. That reaction required an enzymatically active kallikrein. In order to determine the patterns of hydrolysis of major seminal vesicle proteins, semenogelins and fibronectin were exposed to hK2 and to hK3 (prostate-specific antigen or PSA) and cleavage sequences were identified by N-terminal sequencing. Free hK2 was able to hydrolyze semenogelins and fibronectin in vitro. Most of cleavage sites were at the carboxyl-side of arginyl residues. Semenogelins were hydrolyzed to a similar extent by catalytic (and similar) concentration of either hK2 or PSA though no common cleavage sites was identified for both proteinases. Unlike semenogelins, fibronectin was hydrolyzed much more efficiently by hK2 than by PSA. These results show that hK2 is enzymatically active during a short period of time after ejaculation, that major seminal vesicle proteins can be the target of this proteolytic activity, and that hK2 and PSA have different substrate specificities.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9016396

Source DB:  PubMed          Journal:  J Androl        ISSN: 0196-3635


  9 in total

1.  Twenty Years of PSA: From Prostate Antigen to Tumor Marker.

Authors:  Gabriela De Angelis; Harry G Rittenhouse; Stephen D Mikolajczyk; L Blair Shamel; Axel Semjonow
Journal:  Rev Urol       Date:  2007

2.  Specificity of human tissue kallikrein towards substrates containing Phe-Phe pair of amino acids.

Authors:  D C Pimenta; J Chao; L Chao; M A Juliano; L Juliano
Journal:  Biochem J       Date:  1999-04-15       Impact factor: 3.857

3.  Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer.

Authors:  Shahrokh F Shariat; Eduardo I Canto; Michael W Kattan; Kevin M Slawin
Journal:  Rev Urol       Date:  2004

4.  Blocking serine protease activity prevents semenogelin degradation leading to hyperviscous semen in humans.

Authors:  Prashanth Anamthathmakula; Jeffery A Erickson; Wipawee Winuthayanon
Journal:  Biol Reprod       Date:  2022-05-17       Impact factor: 4.161

5.  Genetic variation in KLK2 and KLK3 is associated with concentrations of hK2 and PSA in serum and seminal plasma in young men.

Authors:  Charlotta Sävblom; Christer Halldén; Angel M Cronin; Torbjörn Säll; Caroline Savage; Emily A Vertosick; Robert J Klein; Aleksander Giwercman; Hans Lilja
Journal:  Clin Chem       Date:  2013-11-22       Impact factor: 8.327

6.  Ovarian cancer, the coagulation pathway, and inflammation.

Authors:  Xipeng Wang; Ena Wang; John J Kavanagh; Ralph S Freedman
Journal:  J Transl Med       Date:  2005-06-21       Impact factor: 5.531

7.  Structure-function analyses of human kallikrein-related peptidase 2 establish the 99-loop as master regulator of activity.

Authors:  Wolfgang Skala; Daniel T Utzschneider; Viktor Magdolen; Mekdes Debela; Shihui Guo; Charles S Craik; Hans Brandstetter; Peter Goettig
Journal:  J Biol Chem       Date:  2014-10-16       Impact factor: 5.157

8.  Mechanism of semen liquefaction and its potential for a novel non-hormonal contraception†.

Authors:  Prashanth Anamthathmakula; Wipawee Winuthayanon
Journal:  Biol Reprod       Date:  2020-08-04       Impact factor: 4.285

9.  A Single Glycan at the 99-Loop of Human Kallikrein-related Peptidase 2 Regulates Activation and Enzymatic Activity.

Authors:  Shihui Guo; Wolfgang Skala; Viktor Magdolen; Peter Briza; Martin L Biniossek; Oliver Schilling; Josef Kellermann; Hans Brandstetter; Peter Goettig
Journal:  J Biol Chem       Date:  2015-11-18       Impact factor: 5.157

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.